Sling surgery, robotic approaches to sacrocolpopexy and pelvic organ prolapse, and mesh are among the key studies in the area of female urology to watch for at the 2014 AUA annual meeting.
Richard R. Kerr
Is inflammation a potential target for the treatment of BPH? New research being presented at the 2014 AUA annual meeting may help answer this question.
Research in stone disease and minimally invasive surgery will also make its mark at the Society for Pediatric Urology annual meeting, which runs concurrently with the first 3 days of the AUA meeting.
At the 2012 AUA annual meeting, researchers reported that ureteroscopy had overtaken extracorporeal shock wave lithotripsy (ESWL) as the treatment of choice for kidney stones. Look for research at the 2014 meeting showing that trend is ongoing.
In discussing research at the 2014 AUA annual meeting, Anthony J. Schaeffer, MD, called attention to an important paper concerning urinary tract infection in children, as well as another study showing that antimicrobial prophylaxis after surgery is subject to considerable variation.
Urologists continue to push the limits of minimally invasive surgery, and key papers presented at the AUA meeting will explore the functional and cancer control outcomes associated with minimally invasive and robotic procedures in prostate cancer and renal cell carcinoma. When to use such approaches remains a source of controversy.
The Centers for Medicare & Medicaid Services has issued two new codes that describe the UroLift implant procedure for the treatment of enlarged prostate in the April 2014 Update of the Hospital Outpatient Prospective Payment System (OPPS).
Researchers from the National Institutes of Health have identified new potential therapeutic targets for muscle-invasive bladder cancer, including important genes and pathways that are disrupted in the disease.
Mayo Clinic researchers have found amplification of HER2, a known driver of some breast cancers, in micropapillary urothelial carcinoma and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Both the death rate and incidence rate for prostate cancer continues to decline, according to the latest round of statistics from leading U.S. cancer groups.